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Abstract 
Enzyme-linked immunosorbent assays (ELISA) have been developed which measure 
oestrone glucuronide (El-3G) and pregnanediol glucuronide (PdG) in timed, diluted urine 
samples. Measurement of these urinary metabolites allows information to be collected, 
non-invasively, on the hormonal interplay between the ovaries and the hypothalamic-
pituitary axis, which determines or helps to make predictions about the potentially 
infertile and fertile phases of the human menstrual cycle. 
Immunoglobulin Class G (IgG) antibodies raised in sheep against the analyte of interest 
(El-3G and PdG) were adsorbed onto polystyrene microtitre wells. The enzyme conjugate 
tracer was horseradish peroxidase (HRP), and was prepared by conjugation with either 
El-3G or PdG using the active ester coupling procedure. A direct competitive 
immunoassay configuration in which both analyte and tracer were added to the wells 
simultaneously allowed a direct competition between them for the immobilised antibody 
sites. A chromogenic detection system involving o-phenylenediamine (OPD) was used 
for the measurement of the amount of bound tracer (HRP conjugate) which could be 
related to the amount of analyte in a urine sample. 
The sensitivity of the El-3G assay was 3.4 nmoles/ 24 h, and for the PdG the sensitivity 
was 0.5 µmoles/ 24 h. Both assays were reliable, and were successfully validated against 
World Health Organisation (WHO) assays performed on the same urine samples in a 
multicentre study of the Ovarian Monitor (project #90905). 
The El-3G and PdG reference assays developed in the present study are acceptable for use 
in the laboratory and can be used to validate new non-instrumental colour tests, or other 
home fertility kit assays currently being developed. 
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